Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TARS | Tarsus Pharmaceuticals, Inc.

Index	RUT	P/E	-	EPS (ttm)	-3.40	Insider Own	5.50%	Shs Outstand	32.62M	Perf Week	5.02%
Market Cap	505.28M	Forward P/E	-	EPS next Y	-4.95	Insider Trans	-10.78%	Shs Float	28.42M	Perf Month	-2.31%
Income	-91.00M	PEG	-	EPS next Q	-1.36	Inst Own	77.10%	Short Float / Ratio	15.86% / 10.08	Perf Quarter	-7.12%
Sales	12.50M	P/S	40.42	EPS this Y	-274.90%	Inst Trans	2.29%	Short Interest	4.51M	Perf Half Y	39.62%
Book/sh	5.51	P/B	3.08	EPS next Y	-3.30%	ROA	-42.10%	Target Price	46.00	Perf Year	4.44%
Cash/sh	5.98	P/C	2.83	EPS next 5Y	-	ROE	-50.80%	52W Range	11.33 - 25.25	Perf YTD	15.62%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-29.50%	52W High	-32.87%	Beta	0.76
Dividend %	-	Quick Ratio	12.40	Sales past 5Y	-	Gross Margin	96.80%	52W Low	49.60%	ATR	0.92
Employees	87	Current Ratio	12.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.22	Volatility	5.74% 4.89%
Optionable	Yes	Debt/Eq	0.17	EPS Q/Q	-396.50%	Profit Margin	-	Rel Volume	0.83	Prev Close	16.89
Shortable	Yes	LT Debt/Eq	0.17	Earnings	Aug 10 AMC	Payout	-	Avg Volume	447.22K	Price	16.95
Recom	1.40	SMA20	2.14%	SMA50	-5.11%	SMA200	6.13%	Volume	369,777	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
02:14PM	Loading…
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 04:05PM	Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Loading…
May-08-23 08:30AM	Tarsus Launches Dont Freak Out. Get Checked Out. Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers (GlobeNewswire)
May-05-23 08:22AM	Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price (Simply Wall St.)
May-03-23 04:30PM	Tarsus to Participate at the Bank of America 2023 Healthcare Conference (GlobeNewswire)
Apr-24-23 08:30AM	Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer (GlobeNewswire)
Apr-18-23 06:04AM	Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks) +5.25%
Apr-06-23 03:52PM	Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago (Simply Wall St.)
Mar-17-23 06:28AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Mar-13-23 04:05PM	Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Mar-09-23 10:00AM	Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-02-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 11:44AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months (Simply Wall St.)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Dec-16-22 07:00AM	Tarsus Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-15-22 12:45PM	Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease (Benzinga)
08:30AM	Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
06:55AM	Loading…
Dec-08-22 06:55AM	Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (Simply Wall St.)
Nov-11-22 06:03AM	Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:45AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Oct-25-22 08:30AM	Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 09:26AM	Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago (Simply Wall St.)
Oct-11-22 08:30AM	Tarsus Announces Transition Plans for Board of Directors (GlobeNewswire)
Oct-06-22 08:30AM	Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair (GlobeNewswire)
Sep-29-22 08:30AM	Tarsus Launches Look at the Lids Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis (GlobeNewswire)
Sep-27-22 12:00PM	Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings (GlobeNewswire)
Sep-17-22 10:23AM	The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares (Simply Wall St.)
Sep-07-22 07:00AM	Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Aug-11-22 05:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-22 08:30AM	Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease (GlobeNewswire)
Jul-25-22 08:00AM	Certara Appoints Rosemary Crane as New Independent Board Member (GlobeNewswire)
Jun-29-22 06:51AM	Do Insiders Own Lots Of Shares In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? (Simply Wall St.)
May-27-22 09:00AM	Tarsus to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-14-22 08:19AM	Analysts Just Shipped A Captivating Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates (Simply Wall St.)
May-11-22 06:30AM	The Co-Founder & Independent Chairperson of the Board of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), D. Ackermann, Just Bought 8.3% More Shares (Simply Wall St.)
May-10-22 06:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +11.30%
04:05PM	Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
May-09-22 01:49PM	Further weakness as Tarsus Pharmaceuticals (NASDAQ:TARS) drops 39% this week, taking one-year losses to 63% (Simply Wall St.)
May-06-22 09:00AM	Tarsus to Present at Bank of America 2022 Healthcare Conference (GlobeNewswire) -8.05%
May-05-22 08:30AM	Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting (GlobeNewswire) -6.73%
May-03-22 03:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -6.79%
06:58AM	Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
May-02-22 07:01AM	Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire) -23.54%
07:00AM	Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year (GlobeNewswire)
Apr-29-22 09:23PM	Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Apr-26-22 08:30AM	Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting (GlobeNewswire)
Apr-21-22 03:05AM	E3 Metals Initiates Design of Field Pilot (CNW Group)
Mar-14-22 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements (GlobeNewswire) -5.90%
Mar-09-22 05:00PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-22 09:00AM	Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Feb-02-22 04:30PM	Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03 (GlobeNewswire) -14.15%
07:00AM	Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility (GlobeNewswire)
Jan-04-22 09:00AM	Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors (GlobeNewswire)
Nov-23-21 04:30PM	Tarsus to Participate at Upcoming Virtual Investor Conferences (GlobeNewswire) +7.72%
Nov-10-21 04:30PM	Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021 (GlobeNewswire)
Nov-09-21 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-05-21 12:04PM	Notable Tarsus Pharmaceuticals Insider Makes $160K Sale (Benzinga)
Nov-04-21 11:28AM	Tarsus Pharmaceuticals Insider Sold $160K In Company Stock (Benzinga)
09:45AM	Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting (GlobeNewswire)
Nov-02-21 05:00PM	Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference (GlobeNewswire) -5.49%
Oct-19-21 02:38PM	Insiders of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) are up 80% on their US$2.8m purchase after Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) rose 19% last week (Simply Wall St.)
Oct-11-21 07:43PM	3 Strong Buy Stocks Raymond James Predicts Will Rally Over 60% (TipRanks)
Aug-13-21 07:07AM	Analysts Just Shipped A Dazzling Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates (Simply Wall St.)
Aug-12-21 09:00AM	Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors (GlobeNewswire)
Aug-07-21 04:20AM	Results: Tarsus Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates (Simply Wall St.)
Aug-04-21 05:30PM	Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Jul-24-21 06:00PM	Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021 (GlobeNewswire)
Jul-20-21 08:37AM	We're Hopeful That Tarsus Pharmaceuticals (NASDAQ:TARS) Will Use Its Cash Wisely (Simply Wall St.)
Jul-07-21 04:05PM	Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference (GlobeNewswire)
Jun-26-21 07:34AM	3 Top Biotech Stocks to Buy Right Now (Motley Fool)
Jun-22-21 06:00AM	Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference (GlobeNewswire)
Jun-21-21 12:52PM	Tarsus to submit application for new eye treatment to FDA in 2022 (MarketWatch) -16.69%
07:33AM	Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study (Benzinga)
06:00AM	Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Jun-18-21 04:05PM	Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Jun-16-21 04:05PM	Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
May-24-21 04:05PM	Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-11-21 04:05PM	Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
May-04-21 04:05PM	Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention (GlobeNewswire) -8.30%
May-03-21 04:08PM	Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis (GlobeNewswire)
Apr-27-21 04:05PM	Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference (GlobeNewswire)
Apr-20-21 09:09AM	Who Has Been Buying Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares? (Simply Wall St.)
Mar-31-21 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates (GlobeNewswire) +13.89%
Mar-30-21 07:14AM	Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases (Benzinga)
Mar-29-21 04:05PM	Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease (GlobeNewswire) -6.59%

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azamian Bobak R.	President/CEO and Board Chair	Sep 20	Sale	17.21	8,000	137,680	894,106	Sep 22 05:30 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 23	Sale	17.23	8,000	137,840	902,106	Aug 25 05:12 PM
Lin Elizabeth Yeu	Director	Aug 15	Buy	16.80	9,506	159,701	15,866	Aug 17 06:02 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 19	Sale	20.01	103,900	2,078,984	910,106	Jul 21 05:42 PM
Mottiwala Aziz	Chief Commercial Officer	Jul 19	Sale	20.05	2,400	48,120	45,806	Jul 21 05:46 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 12	Sale	17.35	9,000	156,150	1,014,006	Jul 14 04:40 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 21	Sale	18.63	8,000	149,040	1,023,006	Jun 23 04:29 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 14	Sale	18.58	9,000	167,220	1,031,006	Jun 16 04:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 08	Sale	20.01	3,100	62,031	1,040,006	Jun 12 05:40 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 08	Sale	20.00	100	2,000	48,086	Jun 12 05:25 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 07	Sale	19.34	2,500	48,350	48,186	Jun 08 07:16 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 06	Sale	18.61	2,143	39,881	50,686	Jun 08 07:16 PM
Azamian Bobak R.	President/CEO and Board Chair	May 17	Sale	15.90	8,000	127,200	1,043,106	May 19 07:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 10	Sale	16.80	9,000	151,200	1,051,106	May 12 05:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 01	Sale	15.10	5,841	88,199	1,060,106	May 02 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 28	Sale	15.13	4,278	64,726	1,065,947	May 02 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 21	Sale	15.03	2,311	34,734	1,070,225	Apr 25 05:22 PM
Greenstein Leonard M.	Chief Financial Officer	Apr 20	Sale	14.02	5,000	70,100	26,785	Apr 21 05:53 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 19	Sale	13.60	8,000	108,800	1,072,536	Apr 21 05:49 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 23	Sale	12.15	737	8,955	8,597	Mar 23 07:50 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Mar 23	Sale	12.15	465	5,650	6,107	Mar 23 08:02 PM
Neervannan Seshadri	Chief Operating Officer	Mar 23	Sale	12.15	390	4,738	54,696	Mar 23 07:56 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 23	Sale	12.15	372	4,520	52,829	Mar 23 07:46 PM
Wahl Bryan	General Counsel	Mar 23	Sale	12.15	371	4,508	16,402	Mar 23 07:52 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 23	Sale	12.15	346	4,204	31,785	Mar 23 08:04 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 23	Sale	12.15	345	4,192	11,219	Mar 23 07:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 22	Sale	12.64	709	8,962	9,334	Mar 23 07:50 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Mar 22	Sale	12.64	529	6,687	6,572	Mar 23 08:02 PM
Neervannan Seshadri	Chief Operating Officer	Mar 22	Sale	12.64	379	4,791	55,086	Mar 23 07:56 PM
Wahl Bryan	General Counsel	Mar 22	Sale	12.64	357	4,512	16,773	Mar 23 07:52 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 22	Sale	12.64	357	4,512	53,201	Mar 23 07:46 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 22	Sale	12.64	333	4,209	11,564	Mar 23 07:48 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 22	Sale	12.64	332	4,196	32,131	Mar 23 08:04 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 21	Sale	12.89	679	8,752	10,043	Mar 23 07:50 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Mar 21	Sale	12.89	519	6,690	7,101	Mar 23 08:02 PM
Neervannan Seshadri	Chief Operating Officer	Mar 21	Sale	12.89	372	4,795	55,465	Mar 23 07:56 PM
Wahl Bryan	General Counsel	Mar 21	Sale	12.89	350	4,512	17,130	Mar 23 07:52 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 21	Sale	12.89	349	4,499	53,558	Mar 23 07:46 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 21	Sale	12.89	326	4,202	11,897	Mar 23 07:48 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 21	Sale	12.89	326	4,202	32,463	Mar 23 08:04 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20	Sale	12.61	741	9,344	10,722	Mar 21 07:01 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Mar 20	Sale	12.61	530	6,683	7,620	Mar 21 07:10 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20	Sale	12.61	380	4,792	55,837	Mar 21 07:12 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20	Sale	12.61	358	4,514	53,907	Mar 21 07:08 PM
Wahl Bryan	General Counsel	Mar 20	Sale	12.61	357	4,502	17,480	Mar 21 07:14 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20	Sale	12.61	333	4,199	12,223	Mar 21 07:17 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 20	Sale	12.61	333	4,199	32,789	Mar 21 07:03 PM
Holdbrook Mark J.	V.P., Clinical Affairs	Mar 20	Sale	12.61	198	2,497	3,191	Mar 21 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 17	Sale	13.28	795	10,558	11,463	Mar 21 07:01 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Mar 17	Sale	13.28	504	6,693	8,150	Mar 21 07:10 PM
Neervannan Seshadri	Chief Operating Officer	Mar 17	Sale	13.28	360	4,781	56,217	Mar 21 07:12 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 17	Sale	13.28	339	4,502	54,265	Mar 21 07:08 PM
Wahl Bryan	General Counsel	Mar 17	Sale	13.28	339	4,502	17,837	Mar 21 07:14 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 17	Sale	13.28	316	4,196	12,556	Mar 21 07:17 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 17	Sale	13.28	316	4,196	33,122	Mar 21 07:03 PM
Holdbrook Mark J.	V.P., Clinical Affairs	Mar 17	Sale	13.28	188	2,497	3,389	Mar 21 07:06 PM
Greenstein Leonard M.	Chief Financial Officer	Mar 16	Sale	13.44	5,313	71,404	33,438	Mar 17 06:04 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 16	Sale	13.43	791	10,623	12,258	Mar 17 06:02 PM
Trevejo Jose M.	Chief Medical Officer	Mar 16	Sale	13.43	499	6,702	8,654	Mar 17 06:18 PM
Neervannan Seshadri	Chief Operating Officer	Mar 16	Sale	13.43	357	4,795	56,577	Mar 17 06:15 PM
Wahl Bryan	General Counsel	Mar 16	Sale	13.43	337	4,526	18,176	Mar 17 06:21 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 16	Sale	13.43	336	4,512	54,604	Mar 17 06:17 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 16	Sale	13.43	313	4,204	12,872	Mar 17 06:20 PM
Holdbrook Mark J.	V.P., Clinical Affairs	Mar 16	Sale	13.43	187	2,511	3,577	Mar 17 06:22 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 15	Sale	13.79	8,000	110,320	1,080,536	Mar 17 06:02 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 09	Sale	15.01	717	10,762	1,088,536	Mar 10 05:13 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 08	Sale	15.02	4,853	72,892	1,089,253	Mar 10 05:13 PM
Greenstein Leonard M.	Chief Financial Officer	Feb 16	Sale	15.12	5,000	75,600	34,289	Feb 17 04:58 PM
Azamian Bobak R.	President/CEO and Board Chair	Feb 15	Sale	15.28	8,000	122,240	1,094,106	Feb 17 04:54 PM
Azamian Bobak R.	President/CEO and Board Chair	Feb 08	Sale	15.14	9,000	136,260	1,102,106	Feb 10 04:54 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 23	Sale	15.45	4,856	75,025	1,111,106	Jan 25 05:49 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 20	Sale	15.00	240	3,600	1,116,373	Jan 20 06:41 PM
Greenstein Leonard M.	Chief Financial Officer	Jan 19	Sale	14.56	5,000	72,800	39,289	Jan 20 06:44 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 18	Sale	14.56	8,000	116,480	1,116,613	Jan 20 06:41 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 11	Sale	15.11	3,904	58,989	1,124,613	Jan 13 06:47 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 10	Sale	15.17	905	13,729	1,128,517	Jan 11 08:26 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 09	Sale	15.15	729	11,044	1,129,422	Jan 11 08:26 PM
Azamian Bobak R.	President/CEO and Board Chair	Jan 06	Sale	15.00	411	6,165	1,129,740	Jan 24 06:13 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 21	Sale	14.57	8,000	116,560	1,130,151	Dec 22 06:02 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 16	Sale	15.01	535	8,030	1,138,151	Dec 20 06:35 PM
Greenstein Leonard M.	Chief Financial Officer	Dec 15	Sale	14.64	5,000	73,200	44,289	Dec 16 04:55 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 14	Sale	15.08	6,420	96,814	1,138,686	Dec 16 04:51 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 02	Sale	16.90	1,154	19,503	8,723	Dec 06 05:52 PM
Wahl Bryan	General Counsel	Dec 02	Sale	16.90	1,154	19,503	13,723	Dec 06 05:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 01	Sale	16.75	1,165	19,514	9,877	Dec 01 08:09 PM
Wahl Bryan	General Counsel	Dec 01	Sale	16.75	1,164	19,497	14,877	Dec 01 07:58 PM
Wahl Bryan	General Counsel	Nov 30	Sale	16.50	1,183	19,520	16,041	Dec 01 07:58 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 30	Sale	16.50	1,182	19,503	11,042	Dec 01 08:09 PM
Wahl Bryan	General Counsel	Nov 29	Option Exercise	0.00	10,251	0	17,224	Dec 01 07:58 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 29	Option Exercise	0.00	10,251	0	12,224	Dec 01 08:09 PM
Greenstein Leonard M.	Chief Financial Officer	Nov 17	Sale	16.54	5,000	82,700	49,289	Nov 18 04:12 PM
Azamian Bobak R.	President and CEO	Nov 16	Sale	16.86	8,000	134,852	1,145,106	Nov 18 04:09 PM
Mottiwala Aziz	Chief Commercial Officer	Nov 15	Sale	17.72	6,857	121,506	49,729	Nov 17 05:30 PM
Azamian Bobak R.	President and CEO	Nov 09	Sale	17.87	9,000	160,830	1,153,106	Nov 14 04:25 PM
Greenstein Leonard M.	Chief Financial Officer	Oct 20	Sale	15.92	5,000	79,589	54,289	Oct 28 04:24 PM
Azamian Bobak R.	President and CEO	Oct 19	Sale	16.92	8,000	135,349	1,162,106	Oct 21 04:23 PM
Azamian Bobak R.	President and CEO	Oct 12	Sale	15.91	9,000	143,194	1,170,106	Oct 14 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARS | Tarsus Pharmaceuticals, Inc.

Upgrade your FINVIZ experience